Clinical trial · Observational
Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings
Prognostic Value of Dihydroorotate Dehydrogenase (DHODH) Expression in High-Grade Serous Ovarian Carcinoma: A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* To compare DHODH protein expression in HGSC tissues from patients undergoing Primary Debulking Surgery (PDS - Chemo-naive) versus Interval Debulking Surgery (IDS - Post-NACT). * To evaluate the association between DHODH expression and the degree of chemotherapy response (using the Chemotherapy Response Score - CRS for NACT cases). * To determine the prognostic value of DHODH expression in predicting Platinum-Free Interval (PFI) ,Progression -Free Survival (PFS) and Overall Survival (OS) across both groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HGSOC | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunohistochemical (IHC) assessment of DHODH expression | Other | — | UNRESOLVED |
| No interventions as it is observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group A chemo naive and Group B neoadjuvant group
- description
- Group A (Chemo-naïve group) 36 Patients who underwent primary debulking surgery (PDS) followed by adjuvant platinum-based chemotherapy. Group B (Neoadjuvant group) 36 Patients who received 3-4 cycles of platinum-based neoadjuvant chemotherapy followed by interval debulking surgery (IDS).
- interventionNames
- Other: Immunohistochemical (IHC) assessment of DHODH expression
- Other: No interventions as it is observational study
- label
- Group A (Chemo-naïve group) 36 Patients and Group B (neoadjuvant) group
- description
- Group A (Chemo-naïve group) 36 Patients who underwent primary debulking surgery (PDS) followed by adjuvant platinum-based chemotherapy. Group B (Neoadjuvant group) 36 Patients who received 3-4 cycles of platinum-based neoadjuvant chemotherapy followed by interval debulking surgery (IDS).
- interventionNames
- Other: Immunohistochemical (IHC) assessment of DHODH expression
- Other: No interventions as it is observational study
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed high-grade serous ovarian carcinoma * Availability of adequate FFPE tumor tissue * Known treatment modality (PDS or IDS) * Available clinical follow-up including platinum-free interval and survival data Exclusion Criteria: * Non-serous histological subtypes * Low-grade serous carcinoma * Inadequate tissue for immunohistochemistry * Missing clinical or follow-up data
References
Publications (0)
Data not yet available